Hepatological Aspects of Metabolic Syndrome and Possibilities of Pathogenetic Treatment

V.V. Cherniavskyi, A.K. Sizenko

Abstract


The article deals with the problem of metabolic syndrome and the development of liver failure in patients with this disease. The authors provide evidence about the advisability of administration to such patients of combined medication — ornithine aspartate (original ornithine aspartate Hepa-Merz produced by Merz Pharma GmbH & Co.). Efficiency of Hepa-Merz manifests by a decrease in hepatocyte cytolysis, normalization of lipid and carbohydrate metabolism, as well as positive effects on the clinical presentation of hepatic encephalopathy.


Keywords


metabolic syndrome; liver; ornithine aspartate; Hepa-Merz

References


Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome // Lancet. — 2005. — 365. — Р. 1415-1428.

Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., Fruchart J.C., James W.P., Loria C.M., Smith S.C. Jr. Et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity // Circulation. — 2009. — 120. — Р. 1640-1645.

Hoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance // Journal of Clinical Investigation. — 2008. — 116. — Р. 1793-1801.

Lazar M.A. The humoral side of insulin resistance // Nat. Med. — 2006. — 12. — 43-44.

Li Z., Diehl A.M. Innate immunity in the liver// Curr. Opin. Gastroenterol. — 2003. — 19. — 565-571.

Choi S., Diehl A.M. Role of inflammation in nonalcoholic steatohepatitis // Curr. Opin. Gastroenterol. — 2005. — 21. — 702-707.

Gaemers I.C., Groen A.K. New insights in the pathogenesis of non-alcoholic fatty liver disease // Curr. Opin. Lipidol. — 2006. — 17. — 268-273.

Huang W., Metlakunta A., Dedousis N., Zhang P., Sipula I., Dube J.J., Scott D.K., O’Doherty R.M. Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance // Diabetes. — 2010. — 59. — 347-357.

Lanthier N., Molendi-Coste O., Horsmans Y., van Rooijen N., Cani P.D., Leclercq I.A. Kupffer cell activation is a causal factor for hepatic insulin resistance // Am. J. Physiol. Gastrointest. Liver. Physiol. — 2010. — 298. — G107-G116.

Rondinone C.M., Wang L.M., Lonnroth P., Wesslau C., Pierce J.H., Smith U. Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main dock¬ing protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus // Proc. Natl. Acad. Sci. USA. — 1997. — 94. — 4171-4175.

Zierath J.R., Krook A., Wallberg-Henriksson H. Insulin action in skeletal muscle from patients with NIDDM // Mol. Cell. Biochem. — 1998. — 182. — 153-160.

Kracht M., Saklatvala J. Transcriptional and post-transcriptional control of gene expression in inflammation // Cytokine. — 2002. — 20. — 91-106.

Tsai J., Zhang R., Qiu W., Su Q., Naples M., Adeli K. Inflammatory NF-kappaB activation promotes hepatic apolipoprotein B100 secretion: evidence for a link between hepatic inflammation and lipoprotein production // Am. J. Physiol. Gastrointest. Liver. Physiol. — 2009. — 296. — G1287-G1298.

Gao Z., Zhang X., Zuberi A., Hwang D., Quon M.J., Lefevre M., Ye J. Inhibition of insulin sensitivity by free fatty acids requires activa¬tion of multiple serine kinases in 3T3-L1 adipocytes // Mol. Endocrinol. — 2004. — 18. — 2024-2034.

Cai D., Yuan M., Frantz D.F., Melendez P.A., Hansen L., Lee J., Shoelson S.E. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB // Nat. Med. — 2005. — 11. — 183-190.

Aguirre V., Werner E.D., Giraud J., Lee Y.H., Shoelson S.E., White M.F. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action // J. Biol. Chem. — 2002. — 277. — 1531-1537.

Gao Z., Hwang D., Bataille F., Lefevre M., York D., Quon M.J., Ye J. Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex // J. Biol. Chem. — 2002. — 277. — 48115-48121.

Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., Karin M., Hotamisligil G.S. A central role for JNK in obesity and insulin resistance // Nature. — 2002. — 420. — 333-336.

Ozes O.N., Akca H., Mayo L.D., Gustin J.A., Maehama T., Dixon J.E., Donner D.B. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1 // Proc. Natl. Acad. Sci. USA. — 2001. — 98. — 4640-4645.

Осипенко М.Ф., Редькина А.В., Бикбулатова Е.К., Моисеенко Е.Е., Скалинская М.А., Казакова Е.А. Оценка L-орни­тин-L-аспартата (Гепа-Мерц) в комплексном лечении неалкогольного стеатогепатита // Гастроэнтерология. — 2010. — № 1.

Acharya S.K., Bhatia V., Sreenivas V. et al. // Gastroente­rology. — 2009. — 136 (7). — 2159-68.

Chen M.F., Li R.C., Chen C.H., Gao X.C. // Di Yi Jun Yi Da Xue Xue Bao. — 2005. — 5. — 345-51.

Jiang Q., Jiang X.H., Zheng M.H., Chen Y.P. // J. Gastroenterol. Hepatol. — 2009. — 24 (1). — 9-14.

Kircheis G., Nilius R., Held C. et al. // Hepatology. — 1997. — 25 (6). — 1351-60.

Грюнграйфф К., Ламберт-Бауманн Й. Эффективность гранул L-орнитин-L-аспартата при лечении хронических заболеваний печени // Сучасна гастроентерологія. — 2008. — № 2. — С. 59-67.

Скрипник Н.В., Гриб В.А., Билик Л.Я. Гепатопротекція — шлях до подолання інсулінорезистентності у хворих на цукровий діабет 2-го типу з метаболічним синдромом (огляд літератури) // Діабет і серце. — 2012. — № 10 (166).

Бурков С.Г., Арутюнов А.Г., Годунова С.А., Гурова Н.Ю., Егорова Н.В., Должикова Т.А., Шиковная Ю.Н. Эффективность гранул L-орнитин-L-аспартата в лечении неалкогольной жировой болезни печени // Consilium Medicum Ukraina. — 2010. — № 14.

Кравчун Н.А., Земляницина О.В., Тяжелова О.В. Неалкогольная жировая болезнь печени и сахарный диабет 2-го типа: клиника, диагностика, терапия // Терапія. Гастроентерологія. — 2012. — № 3-4 (1).




DOI: https://doi.org/10.22141/2308-2097.4.54.2014.82022

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru